The company’s bottom line improved, too. Adjusted EBITDA increased 350% to $11.7-million from the $2.2-million the company reported in Q1 2011.
Byron Capital Healthcare analyst Douglas Loe says that although Centric’s margins grew to 11.2% from 8.1% in Q4, they remain below the industry average of 12.5% to 13%, and well below the 15% margins Loe expects the company to post by the second half of 2013. Still, the Byron analyst believes that the numbers are solid, considering the feverish pace of Centric’s acquisition spree. In a research update to clients today, Loe Maintain BUY rating and $2.00 target price.
_
This story is brought to you by Agrimarine (TSXV:FSH). Not all salmon farms are the same. Click here to learn how Agrimarine is meeting consumer demand for sustainable aquaculture.
__
Founded in 2001, Toronto’s Centric Health provides a range of healthcare services including medical assessments, rehabilitation management and physiotherapy. The company has quietly become a player in the Canadian healthcare services field, having grown its revenue from $15.7-million in fiscal 2008 to more than $200-million in 2011. The physiotherapy market has become a focus for Centric. In Q1 alone, the The company expanded its national physiotherapy footprint through the acquisition of five physiotherapy businesses.
Loe says physiotherapy, having generated $45.1 million in revenue at a 15.5% margin, is a bright spot for Centric. The company’s performance in that area, he says, is covering for softer margins in the company’s surgical and medical centers, and in pharmacy.
Share of Centric Health closed today down 5% to $1.13.
___________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________
In an April 1 report, Roth Capital Markets analyst Scott Searle maintained his “Buy” rating and $180.00 target on Universal… [Read More]
In a March 31 report, Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$5.50 target on NervGen… [Read More]
In a March 31 initiation, Ventum Capital Markets analyst Amr Ezzat launched coverage of NTG Clarity Networks (NTG Clarity Networks… [Read More]
In an appearance on BNN Bloomberg Market Call on March 31, Propellus Wealth Partners portfolio manager and senior wealth advisor… [Read More]
In a March 31 report, RBC economist Abbey Xu said the Canadian economy started 2026 on firmer footing than expected,… [Read More]
In a March 31 report, Roth Capital Markets analyst Rohit Kulkarni maintained his “Buy” rating on zSpace (zSpace Stock Quote,… [Read More]